ESMO 2023 | Neoadjuvant and adjuvant strategies in localized MIBC: current approaches and future directions

Daniele Raggi, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the evolving landscape of managing T2N0M0 urothelial carcinoma (UCa), focusing on muscle-invasive bladder cancer. The neoadjuvant approach before radical cystectomy addresses ineligibility for cisplatin-based chemo or major surgery. Adjuvant uncertainties exist, with ongoing studies assessing cisplatin, immunotherapy, and targeted therapies. Dr Raggi explores immuno-oncology in the perioperative setting, highlighting interim signals on checkpoint inhibitors’ clinical activity. This insightful perspective was shared at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR) 2023 in Malaga, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.